Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.9.3951

Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy  

Xiao, Yang (Department of Medical Oncology, The People's Hospital of Taixing City)
Liu, Jun (Department of Medical Oncology, The People's Hospital of Taixing City)
Liu, Yang-Chen (Department of Medical Oncology, The People's Hospital of Taixing City)
Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Guo, Jian-Xong (Department of Medical Oncology, The People's Hospital of Taixing City)
Wei, Wei (Department of Medical Oncology, The People's Hospital of Taixing City)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.9, 2014 , pp. 3951-3954 More about this Journal
Abstract
Objective: To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Methods: Patients who received highly emetogenic chemotherapy were randomly assigned to a treatment group (60 patients) treated with EANI combined with hydrochloride palonosetron, and control group (also 60 patients) given only hydrochloride palonosetron. Chemotherapy related nausea and vomiting were observed and recorded in both groups of patients from the start till the end of chemotherapy. Results: Complete control rates of vomiting in treatment and control group were 40%, and 35%, respectively, without any statistical ly significant difference (p>0.05); however the response rates are 95.0%, 78.3%, respectively, with statistical difference (p<0.05). Complete control rates of nausea in treatment and control group were 36.7%, 30%, respectively, without statistical difference (p>0.05); but the response rates are 90.0%, 76.7%, respectively, with statistical difference (p<0.05). Conclusion: EANI combined with hydrochloride palonosetron for prevention of nausea and vomiting induced by chemotherapy could be more effective than hydrochloride palonosetron alone, and can be recommended for use in prevention and treatment of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Keywords
Electronic anti-nausea instrument; palonosetron; chemotherapy; nausea/vomitting;
Citations & Related Records
Times Cited By KSCI : 20  (Citation Analysis)
연도 인용수 순위
1 Yan HA, Shen K, Huang XE (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4.   과학기술학회마을   DOI   ScienceOn
2 Wei G, Nie MM, Shen XJ, et al (2014). Experimental study on sustained-release 5-Fluorouracil implantation in canine peritoneum and para-aortic abdominalis. Asian Pac J Cancer Prev, 15, 407-11.   DOI   ScienceOn
3 Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22.   과학기술학회마을   DOI   ScienceOn
4 Xu X, Wang L, Xu HQ, et al (2013). Clinical comparison between paclitaxel liposome ($Lipusu^{(R)}$) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 14, 2591-4.   과학기술학회마을   DOI   ScienceOn
5 Yusuf A, Ahmad Z, Keng SL et al (2013). Quality of life in Malay and Chinese women newly diagnosed with breast cancer in Kelantan, Malaysia. Asian Pac J Cancer Prev, 14, 435-40.   과학기술학회마을   DOI   ScienceOn
6 Tas D, Uncu D, Sendur MA, et al (2014). Acupuncture as a complementary treatment for cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 15, 3139-44.   과학기술학회마을   DOI   ScienceOn
7 Kubota H, Taguchi K, Kobayashi D, et al (2013). Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer. Asian Pac J Cancer Prev, 14, 7107-10.   과학기술학회마을   DOI   ScienceOn
8 Li CH, Liu MY, Liu W, et al (2014). Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 731-6.   과학기술학회마을   DOI   ScienceOn
9 Rabasseda X.Ramosetron (2002). 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc), 38, 75-89.   DOI
10 Wang JY, Cai Y (2013). Clinical observation and prognostic analysis of pemetrexed plus platinum as first-line treatment in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 6267-71.   과학기술학회마을   DOI   ScienceOn
11 Wang M, Gu J, Wang HX, et al (2013). Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy. Asian Pac J Cancer Prev, 13, 4153-6.   과학기술학회마을   DOI   ScienceOn
12 Wang SY, Zhu WH, Vargulick S, et al (2013). Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Asian Pac J Cancer Prev, 14, 5995-6000.   과학기술학회마을   DOI   ScienceOn
13 Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4.   과학기술학회마을   DOI   ScienceOn
14 Dranitsaris G, Leung P, Ciotti R, et al (2001). A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. Pharmacoeconomics, 19, 955-67.   DOI   ScienceOn
15 Keat CH, Ghani NA (2013). Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. Asian Pac J Cancer Prev, 14, 7701-6.   과학기술학회마을   DOI   ScienceOn
16 Fu JH, Gao Z, Ren CC, et al (2013). Comparison of clinical efficacy of three different neoadjuvant approaches (chemotherapy combined vaginal intracavitary irradiation, neoadjuvant chemotherapy alone or radiotherapy) combined with surgery for patients with stage Ib2 and IIa2 cervical cancer. Asian Pac J Cancer Prev, 14, 2377-81.   과학기술학회마을   DOI   ScienceOn
17 Ingersoll GL, Wasilewski A, Haller M, et a1 (2010). Effect of concord grape juice on chemotherapy-induced nausea and vomiting results of a pilot study. Oncol Nurs Forum, 37, 213-21.   DOI   ScienceOn
18 Jordan K, Kasper C, Schmoll HJ (2005). Chemotherapy-induced nausea and vomiting: Current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer, 41, 199.   DOI   ScienceOn
19 Keat CH, Phua G, Abdul Kassim MS, et al (2013). Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy? Asian Pac J Cancer Prev, 14, 469-73   과학기술학회마을   DOI   ScienceOn
20 Abe H, Mori T, Kawai Y, et al (2013). Feasibility study of docetaxel and cyclophosphamide six- cycle therapy as adjuvant chemotherapy for Japanese human epidermal growth factor receptor 2-negative breast cancer patients. Asian Pac J Cancer Prev, 14, 4835-8.   과학기술학회마을   DOI   ScienceOn
21 Akkuzu G, Talas MS, Ortac F (2014). Functional status in Turkish women with gynecological cancer. Asian Pac J Cancer Prev, 15, 2045-9.   과학기술학회마을   DOI   ScienceOn
22 Akyuz RG, Ugur O, Elcigil A (2013). Sleep quality in lung cancer patients. Asian Pac J Cancer Prev, 14, 2909-13.   과학기술학회마을   DOI   ScienceOn
23 Uygun K, Bilici A, Kaya S, et al (2013). XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions. Asian Pac J Cancer Prev, 14, 2283-8.   과학기술학회마을   DOI   ScienceOn
24 Baykara M, Buyukberber S, Ozturk B, et al (2013). Efficacy and safety of concomitant chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced squamous cell head and neck cancers. Asian Pac J Cancer Prev, 14, 2557-61.   과학기술학회마을   DOI   ScienceOn